Clinical trials: Hematological Cancer
Hematological Malignancy (Leukemia- Lymphoma)
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19…
- Trial name
- NCT07131254
- Testing
- GT719 Injection
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Grit Biotechnology
Solid and Hematological Malignancies
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
This is a two-part, open-label, randomized, crossover study in healthy subjects (vasectomized males and women of non-childbearing potential), performed at 2 study centers
- Trial name
- NCT04944771
- Testing
- Capivasertib, Rabeprazole
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chemotherapy-induced Thrombocytopenia
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung…
- Trial name
- NCT03471078
- Testing
- Avatrombopag
- Where
- 55 sites in United States, China and 5 more
- Volunteers
- 122 people
- Sponsor
- Sobi, Inc.
Hematological Malignancies
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitors (HTLP)) injection to accelerate immune reconstitution after haploidentical hematopoietic stem cell transplantation…
- Trial name
- NCT05768035
- Testing
- Allogeneic T cell progenitors, cultured ex-vivo
- Where
- 4 sites in France
- Volunteers
- 40 people
- Sponsor
- Smart Immune SAS
Lymphoma, B-Cell, T-Cell Lymphoma
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with hematologic malignancies.
- Trial name
- PI3K (NCT02017613)
- Testing
- RP6530
- Where
- 3 sites in France, Italy
- Volunteers
- 35 people
- Sponsor
- Rhizen Pharmaceuticals SA
Hematological Malignancies
M-2018-334 in Hematological Malignancies
This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.
- Trial name
- HAPLO2022 (NCT06225050)
- Testing
- CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Miltenyi Biomedicine GmbH
Acute Myeloid Leukemia
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
This was a parallel, Phase 1/Phase 2, randomized, open label, multi-cohort, multi-center study assessing the safety, tolerability and preliminary efficacy of SAR443579 with different agents for treatment in adolescent and/or…
- Trial name
- NCT06508489
- Testing
- SAR443579, venetoclax, azacitidine
- Where
- 7 sites in United States, Australia
- Volunteers
- 7 people
- Sponsor
- Sanofi
Multiple Myeloma, Acute Myeloid Leukemia
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome
- Trial name
- NCT03465540
- Testing
- AMG 397, Dexamethasone, Azacitidine
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 24 people
- Sponsor
- Amgen
Hematologic Neoplasms
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
The purpose of this study is to investigate the hypothesis that the efficacy of intravenous (IV) itraconazole followed by oral itraconazole is non-inferior to that of intravenous caspofungin as empiric therapy for suspected…
- Trial name
- NCT02895529
- Testing
- Itraconazole, Caspofungin
- Where
- 12 sites in China
- Volunteers
- 61 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Hematological Malignancies
Study of IV CBL0137 in Previously Treated Hematological Subjects
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV)…
- Trial name
- NCT02931110
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incuron
Chronic Lymphocytic Leukemia, CLL
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.
- Conditions
- Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
- Trial name
- NCT06697184
- Testing
- Sonrotoclax, Zanubrutinib
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 258 people
- Sponsor
- BeOne Medicines
Mycoses, Leukemia
Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)
This will be a retrospective study that includes retrospective chart reviews at major institutions across Canada. The intent of the study is to generate both regional and national incidence data for non-Candida invasive fungal…
- Trial name
- TRAFIC (NCT01254318)
- Testing
- Standard Care
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM
- Trial name
- NCT02071888
- Testing
- CB-839, CB-839 and low dose dexamethasone, CB-839, pomalidomide, and low dose dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Calithera Biosciences, Inc
Hematologic Neoplasms
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
- Trial name
- NCT00595686
- Testing
- SNX-5422
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Esanex Inc.
Lymphoma, Multiple Myeloma
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
The purpose of this clinical trial is to learn how the experimental medicine maplirpacept (PF-07901801) affects people with various types of blood cancers: relapsed or refractory (R/R) lymphoma multiple myeloma newly diagnosed…
- Conditions
- Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03530683
- Testing
- Maplirpacept (PF-07901801), Azacitidine, Venetoclax
- Where
- 62 sites in United States
- Volunteers
- 189 people
- Sponsor
- Pfizer
Advanced Solid Tumors, Hematological Malignancies
A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies
This is a Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological…
- Trial name
- ATRIUM (NCT05338346)
- Testing
- ATG-018
- Where
- 5 sites in Australia
- Volunteers
- 22 people
- Sponsor
- Antengene Discovery Limited
Solid Tumor, Hematological Malignancy
A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies
The purpose of this study is to evaluate the plasma concentration and pharmacodynamics effects of warfarin 5 mg, in the presence or absence of belinostat 1,000 mg/m².
- Trial name
- NCT01317927
- Testing
- Belinostat, Warfarin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Hematological Malignancy
DxFLEX 10C Clinical Study
A multi-center method comparison study is designed per CLSI-EP09 A3. This study compares the qualitative immunophenotype agreement between DxFLEX and Navios EX to demonstrate the accuracy of the DxFLEX-10C system.
- Trial name
- NCT05467449
- Testing
- DxFLEX 10C
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 527 people
- Sponsor
- Beckman Coulter, Inc.
AML, ALL
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
This is a multicenter, open-label, dose escalation Phase 1 study.
- Conditions
- AML, ALL, Blast Crisis, MDS
- Trial name
- TG02-101 (NCT01204164)
- Testing
- TG02 citrate, Carfilzomib, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or…
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma
- Trial name
- NCT04977024
- Testing
- COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- GeoVax, Inc.